相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inactivation of the superoxide dismutase by malondialdehyde in the nonalcoholic fatty liver disease: a combined molecular docking approach to clinical studies
Arash Arya et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2021)
Low-dose cadmium exposure acts on rat mesenchymal stem cells via RANKL/OPG and downregulate osteogenic differentiation genes
Ying-Jian Lv et al.
ENVIRONMENTAL POLLUTION (2019)
Heamatococcus pluvialis ameliorates bone loss in experimentally-induced osteoporosis in rats via the regulation of OPG/RANKL pathway
Farouk K. El-Baz et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Quantifying RANKL and OPG levels in healthy children: A large cross-sectional analysis
Sara Akhtar Ali et al.
BONE (2019)
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment
Peter A. van Dam et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes
A. Mantovani et al.
DIABETES & METABOLISM (2019)
Examination of OPG, RANK, RANKL and HIF1A polymorphisms in temporomandibular joint ankylosis patients
Paola Fernanda Cotait de Lucas Corso et al.
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2019)
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
Irene Pierantonelli et al.
TRANSPLANTATION (2019)
New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Xu Zhang et al.
PROTEIN & CELL (2018)
Estradiol-mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPK, and miR-221
Anastasija Panic et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2018)
Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease
Lucia Pacifico et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score)
Witigo von Schoenfels et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2018)
Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: Irrespective of obesity
Mehrnoosh Shanaki et al.
PLOS ONE (2018)
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
Rafal Filip et al.
CLINICAL INTERVENTIONS IN AGING (2018)
The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease
Hannah Forde et al.
CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM (2018)
A study on OPG/RANK/RANKL axis in osteoporotic bile duct-ligated rats and the involvement of nitrergic and opioidergic systems
Amir Hossein Doustimotlagh et al.
RESEARCH IN PHARMACEUTICAL SCIENCES (2018)
Nonalcoholic Fatty Liver Disease
Patrick H. Sweet et al.
PRIMARY CARE (2017)
Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease
Flavia A. Cimini et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: A case-control study in China
Yixin Niu et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?
G. Targher et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2015)
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis
Mei Yang et al.
PLOS ONE (2015)
The Relation Between Carotid Intima Media Thickness and Serum Osteoprotegerin Levels in Nonalcoholic Fatty Liver Disease
Teslime Ayaz et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2014)
Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk
Y. Yilmaz
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease
Yusuf Yilmaz et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2010)
Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?
Doris Wagner et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2010)
Pathophysiological roles of osteoprotegerin (OPG)
Penny Reid et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2009)
OPG/RANK/RANKL signaling system and its significance in nephrology
Katarzyna Klejna et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2009)
High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue
Nuria Guanabens et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2009)
Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway
Estelle Chamoux et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation:: relationship with metabolic bone disease
Ana Monegal et al.
LIVER INTERNATIONAL (2007)
Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene
A Bashir et al.
STEROIDS (2005)
The RANKL/OPG system and bone mineral density in patients with chronic liver disease
AR Moschen et al.
JOURNAL OF HEPATOLOGY (2005)
Osteoprotegerin and RANKL in alcoholic liver cirrhosis
E Fábrega et al.
LIVER INTERNATIONAL (2005)
Soluble RANKL and risk of nontraumatic fracture
G Schett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis
F Szalay et al.
JOURNAL OF HEPATOLOGY (2003)
Decreased bone density, elevated serum osteoprotegerin, and β-cross-laps in Wilson disease
D Hegedus et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
LC Hofbauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
分享论文
